$-0.10 EPS Expected for Organovo Holdings, Inc. (ONVO); MARINUS PHARMACEUTICALS (MRNS) Has 2.8 Sentiment

January 19, 2018 - By Darrin Black

Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. The company has market cap of $278.16 million. The firm is developing ganaxolone, a small molecule, which is in Phase III clinical trials to treat adults with refractory focal onset epileptic seizures; and is in Phase II clinical trials for the treatment of genetic orphan disorders, as well as is in Phase II clinical trial to treat Fragile X Syndrome, an orphan indication. It currently has negative earnings. The firm is also developing ganaxolone IV formulation to treat status epilepticus.

Analysts expect Organovo Holdings, Inc. (NASDAQ:ONVO) to report $-0.10 EPS on February, 8.They anticipate $0.01 EPS change or 11.11% from last quarter’s $-0.09 EPS. After having $-0.09 EPS previously, Organovo Holdings, Inc.’s analysts see 11.11% EPS growth. It closed at $1.37 lastly. It is down 12.50% since January 19, 2017 and is uptrending. It has underperformed by 4.20% the S&P500.

Organovo Holdings, Inc., an early commercial stage company, creates and creates functional and three-dimensional human tissues for use in medical research and therapeutic applications. The company has market cap of $146.49 million. The firm develops 3D human tissue models through internal development and in collaboration with pharmaceutical, academic, and other partners. It currently has negative earnings. The Company’s 3D human tissues could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs.

Investors sentiment decreased to 1.53 in Q3 2017. Its down 0.02, from 1.55 in 2017Q2. It dropped, as 11 investors sold Organovo Holdings, Inc. shares while 19 reduced holdings. 11 funds opened positions while 35 raised stakes. 24.05 million shares or 7.12% more from 22.45 million shares in 2017Q2 were reported. Tiaa Cref Inv Ltd Company owns 312,886 shares for 0% of their portfolio. Moreover, Bnp Paribas Arbitrage Sa has 0% invested in Organovo Holdings, Inc. (NASDAQ:ONVO) for 8,932 shares. Rhumbline Advisers reported 112,124 shares or 0% of all its holdings. 5,954 were accumulated by Barclays Pcl. Great West Life Assurance Can owns 4,015 shares for 0% of their portfolio. Ameritas Ptnrs Incorporated owns 8,100 shares. 1.70 million were accumulated by State Street. Amer Financial Grp Inc reported 0.06% stake. Royal National Bank Of Canada invested 0% in Organovo Holdings, Inc. (NASDAQ:ONVO). Invest House Limited Liability Corporation has invested 0% of its portfolio in Organovo Holdings, Inc. (NASDAQ:ONVO). Raymond James And Assocs has 46,429 shares. 162,036 are owned by California State Teachers Retirement Systems. Natl Bank Of Montreal Can holds 869 shares or 0% of its portfolio. Wells Fargo & Mn reported 161,970 shares. Peconic Prns owns 24,000 shares.

Granite Point Capital Management L.P. holds 3.32% of its portfolio in Marinus Pharmaceuticals, Inc. for 2.68 million shares. Ecor1 Capital Llc owns 3.62 million shares or 2.83% of their US portfolio. Moreover, New Leaf Venture Partners L.L.C. has 0.68% invested in the company for 250,000 shares. The New York-based Iguana Healthcare Management Llc has invested 0.57% in the stock. Deerfield Management Co, a New York-based fund reported 1.36 million shares.

Since January 1, 0001, it had 0 buys, and 1 sale for $10.02 million activity.

The stock increased 7.33% or $0.47 during the last trading session, reaching $6.88. About 1.31M shares traded. Marinus Pharmaceuticals, Inc. (MRNS) has declined 74.89% since January 19, 2017 and is downtrending. It has underperformed by 91.59% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts